Complications of midgut carcinoid tumors and carcinoid syndrome

Neuroendocrinology

Volumn 80, Issue SUPPL. 1, 2004, Pages 28-32

  Van Der Horst Schriversa, Anouk N A ^a   Machteld Wymengaa, A N ^a   Linksb, Thera P ^a   Willemsea, Pax H B ^a   Kemac, Ido P ^a   De Vriesa, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Carcinoid syndrome; Carcinoid tumors; Complications

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOGENIC AMINE; DIURETIC AGENT; FLUOROLEVODOPA F 18; INTERFERON; LOPERAMIDE; NICOTINIC ACID; OCTREOTIDE; PANCREAS ENZYME; POLYPEPTIDE; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; TRYPTOPHAN; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CARCINOID SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DIARRHEA; DIGESTIVE SYSTEM TUMOR; ENZYME THERAPY; FLUSHING; FOLLOW UP; HUMAN; HYPERTENSION; INTESTINE ISCHEMIA; MALABSORPTION; MENTAL DISEASE; MIDGUT; PELLAGRA; PRIORITY JOURNAL; PULMONARY VALVE DISEASE; RETROPERITONEAL FIBROSIS; TRICUSPID VALVE DISEASE; WHEEZING;

CARCINOID HEART DISEASE; CARCINOID TUMOR; DIARRHEA; FLUSHING; FOLLOW-UP STUDIES; HUMANS; MALIGNANT CARCINOID SYNDROME; MENTAL DISORDERS; MODELS, BIOLOGICAL; PELLAGRA; RESPIRATORY SOUNDS; SEROTONIN; STOMACH NEOPLASMS;

EID: 6044221567     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080737     Document Type: Conference Paper

References (55)

1. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-959.
2. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295-1300.
3. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963;i:238-239.
4. Thorson A, Biorck G, Borkman G, Waldenstrom J: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47:795-817.
5. Feldman JM: Carcinoid tumors and syndrome. Semin Oncol 1987;14:237-246.
6. Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG: Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46:1588-1596.
7. Oberg K: Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-463.
8. Kema IP, de Vries EG, Muskiet FA: Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000;747:33-48.
9. Talamonti MS, Stuart KE, Yao JC: Neuroendocrine tumors of the gastrointestinal tract: How aggressive should we be? Am Soc Clin Oncol Educ Book 2004;206-218.
10. Bax ND, Woods HF, Batchelor A, Jennings M: Clinical manifestations of carcinoid disease. World J Surg 1996;20:142-146.
11. Soga J, Yakuwa Y, Osaka M: Carcinoid syndrome: A statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999;18:133-141.
12. Haster WI: Motility of the small intestine and colon; in Yamada T (ed): Textbook of Gastroenterology, ed 4. Philidephia, Lippincott Williams and Wilkins, 2003, vol 1, pp 221-247.
13. Van der Ohe MR, Camilleri M, Kvols LK, Thomforde GM: Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993;329:1073-1078.
14. Oberg K, Theodorsson-Norheim E, Norheim I: Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements. Scand J Gastroenterol 1987;22:1041-1048.
15. Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K Tiensuu Janson E, Akerstrom G: Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002;26:991-997.
16. Nave H, Mossinger E, Feist H, Lang H, Raab H: Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years. Surgery 2001;129:170-175.
17. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666.
18. Oberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-133.
19. Gustafsen J, Lendorf A, Raskov H, Boesby S: Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol 1986;21:816-818.
20. Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH: Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 1998;34:1293-1294.
21. Gustafsen J, Boesby S, Man WK: Histamine in carcinoid syndrome. Agents Actions 1988;25:1-3.
22. Matuchansky C, Launay JM: Serotonin, catecholamines, and spontaneous midgut carcinoid flush: Plasma studies from flushing and nonflushing sites. Gastroenterology 1995;108:743-751.
23. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K: Tachykinins in carcinoid tumors: Their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605-612.
24. Richter G, Stockmann F, Conlon JM, Creutzfeldt W: Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 1986;91:612-618.
25. Noppen M, Jacobs A, Van Belle S, Herregodts P, Somers G: Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome. Br Med J 1988;296:682-683.
26. Wymenga AN, de Monchy JG, de Vries EG: The carcinoid syndrome and angioedema. Ann Intern Med 1995;123:636.
27. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E: Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-269.
28. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609-1615.
29. Himelman RB, Schiller NB: Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 1989;63:347-352.
30. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
31. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, Levy RJ: Serotonin mechanisms in heart valve disease. 1. Serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161:2111-2121.
32. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig Lipson S, McGonigle P, Levy RJ, Liang B: Serotonin mechanisms in heart valve disease. 2. The 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002;161:2209-2218.
33. Denney WD, Kemp WE Jr, Anthony LB, Oates JA, Byrd BF 3rd: Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol 1998;32:1017-1022.
34. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA: Factors associated with progression of carcinoid heart disease. N Engl J Med 2003;348:1005-1015.
35. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK: Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995;25:410-416.
36. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-1196.
37. van der Horst-Schrivers AN, Wymenga AN, de Vries EG: Carcinoid heart disease. N Engl J Med 2003;348:2359-2361.
38. Robiolio PA, Rigolin VH, Harrison JK, Lowe JE, Moore JO, Bashore TM, Feldman JM: Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995;75:485-488.
39. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA: Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994;40:86-95.
40. Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG: Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 2003;49:586-593.
41. Hoffmann J, Grimm W, Menz V, Wied M, Funck R, Arnold R, Maisch B: Heart rate variability in carcinoid heart disease. Am J Cardiol 1999;83:128-131, A9.
42. Hoffmann J, Grimm W, Menz V, Wied M, Sprenger A, Arnold R, Maisch B: Prognostic value of heart rate variability analysis in patients with carcinoid syndrome. Digestion 2001;63:35-42.
43. Meijer WC, van Veldhuisen DJ, Kema IP, Van den Berg MP, Boomsma F, Willemse PH de Vries EG: Cardiovascular abnormalities in patients with a carcinoid syndrome. Neth J Med 2002;60:10-16.
44. Strobbe L, D'Hondt E, Ramboer C, Ceuppens H, Hinnekens P, Verhamme M: Ileal carcinoid tumors and intestinal ischemia. Hepatogastroenterology 1994;41:499-502.
45. Eckhauser FE, Argenta LC, Strodel WE, Wheeler RH, Bull FE, Appelman HD, Thompson NW: Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 1981;90:720-728.
46. Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P, Akerstrom G: Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 2000;24:1402-1408.
47. Kucuk O, Noskin G, Petersen K, Ezdinli E, Rollins D, Singh S, Sarpel S: Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer 1988;62:1026-1029.
48. Dev S, al Dujaily S, Subbuswamy SG: A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad Med J 1999;75:38-40.
49. Sakai D, Murakami M, Kawazoe K, Tsutsumi Y: Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis. Pathol Int 2000;50:404-411.
50. Hegyi J, Schwartz RA, Hegyi V: Pellagra: Dermatitis, dementia, and diarrhea. Int J Dermatol 2004;43:1-5.
51. Russo S, Nielen MM, Boon JC, Kema IP, Willemse PH, de Vries EG, Korf J, den Boer JA: Neuropsychological investigation into the carcinoid syndrome. Psychopharmacology 2003;168:324-328.
52. Russo S, Boon JC, Kema IP, Willemse PH, den Boer JA, Korf J, de Vries EG: Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med 2004;66:422-425.
53. Larsson G, Sjoden PO, Oberg K, Eriksson B, von Essen L: Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol 2001;40:825-831.
54. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003;10:459-462.
55. Kema IP, de Vries EG, Schellings AM, Postmus PE, Muskiet FA: Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 1992;384:534-540.